97 related articles for article (PubMed ID: 9453570)
1. Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives: uptake by dopamine transporter and activity to induce parkinsonism.
Kawai H; Makino Y; Hirobe M; Ohta S
J Neurochem; 1998 Feb; 70(2):745-51. PubMed ID: 9453570
[TBL] [Abstract][Full Text] [Related]
2. Endogenous neurotoxic dopamine derivative covalently binds to Parkinson's disease-associated ubiquitin C-terminal hydrolase L1 and alters its structure and function.
Contu VR; Kotake Y; Toyama T; Okuda K; Miyara M; Sakamoto S; Samizo S; Sanoh S; Kumagai Y; Ohta S
J Neurochem; 2014 Sep; 130(6):826-38. PubMed ID: 24832624
[TBL] [Abstract][Full Text] [Related]
3. Dopamine transporter and catechol-O-methyltransferase activities are required for the toxicity of 1-(3',4'-dihydroxybenzyl)-1,2,3, 4-tetrahydroisoquinoline.
Kawai H; Kotake Y; Ohta S
Chem Res Toxicol; 2000 Dec; 13(12):1294-301. PubMed ID: 11123971
[TBL] [Abstract][Full Text] [Related]
4. Structural significance of azaheterocyclic amines related to Parkinson's disease for dopamine transporter.
Matsubara K; Senda T; Uezono T; Fukushima S; Ohta S; Igarashi K; Naoi M; Yamashita Y; Ohtaki K; Hayase N; Akutsu S; Kimura K
Eur J Pharmacol; 1998 May; 348(1):77-84. PubMed ID: 9650834
[TBL] [Abstract][Full Text] [Related]
5. Uptake of a neurotoxin-candidate, (R)-1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline into human dopaminergic neuroblastoma SH-SY5Y cells by dopamine transport system.
Takahashi T; Deng Y; Maruyama W; Dostert P; Kawai M; Naoi M
J Neural Transm Gen Sect; 1994; 98(2):107-18. PubMed ID: 7734108
[TBL] [Abstract][Full Text] [Related]
6. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium.
Pifl C; Giros B; Caron MG
J Neurosci; 1993 Oct; 13(10):4246-53. PubMed ID: 8410185
[TBL] [Abstract][Full Text] [Related]
7. Striatal transporter for dopamine: catechol structure-activity studies and susceptibility to chemical modification.
Meiergerd SM; Schenk JO
J Neurochem; 1994 Mar; 62(3):998-1008. PubMed ID: 8113819
[TBL] [Abstract][Full Text] [Related]
8. The dopamine transporter. The cloned target site of parkinsonism-inducing toxins and of drugs of abuse.
Pifl C; Giros B; Caron MG
Adv Neurol; 1996; 69():235-8. PubMed ID: 8615133
[No Abstract] [Full Text] [Related]
9. Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity.
Van Kampen JM; McGeer EG; Stoessl AJ
Synapse; 2000 Sep; 37(3):171-8. PubMed ID: 10881039
[TBL] [Abstract][Full Text] [Related]
10. A rapid and reversible change in dopamine transporters induced by methamphetamine.
Fleckenstein AE; Metzger RR; Gibb JW; Hanson GR
Eur J Pharmacol; 1997 Apr; 323(2-3):R9-10. PubMed ID: 9128855
[TBL] [Abstract][Full Text] [Related]
11. Tetrahydropapaveroline and its derivatives inhibit dopamine uptake through dopamine transporter expressed in HEK293 cells.
Okada T; Shimada S; Sato K; Kotake Y; Kawai H; Ohta S; Tohyama M; Nishimura T
Neurosci Res; 1998 Jan; 30(1):87-90. PubMed ID: 9572583
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of striatal dopamine transporter activity by 17beta-estradiol.
Disshon KA; Boja JW; Dluzen DE
Eur J Pharmacol; 1998 Mar; 345(2):207-11. PubMed ID: 9600639
[TBL] [Abstract][Full Text] [Related]
13. The 5-HT3 receptor agonist 1-(m-chlorophenyl)-biguanide interacts with the dopamine transporter in rat brain synaptosomes.
Campbell AD; Womer DE; Simon JR
Eur J Pharmacol; 1995 Jul; 290(2):157-62. PubMed ID: 8575531
[TBL] [Abstract][Full Text] [Related]
14. Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes.
Cowell RM; Kantor L; Hewlett GH; Frey KA; Gnegy ME
Eur J Pharmacol; 2000 Feb; 389(1):59-65. PubMed ID: 10686296
[TBL] [Abstract][Full Text] [Related]
15. Translocation of dopamine and binding of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers.
Xu C; Coffey LL; Reith ME
Biochem Pharmacol; 1995 Jan; 49(3):339-50. PubMed ID: 7857321
[TBL] [Abstract][Full Text] [Related]
16. Implication of dopamine transporter system on 1-methyl-4-phenylpyridinium and rotenone effect in striatal synaptosomes.
Bougria M; Vitorica J; Cano J; Machado A
Eur J Pharmacol; 1995 Nov; 291(3):407-15. PubMed ID: 8719427
[TBL] [Abstract][Full Text] [Related]
17. Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations.
Chi L; Reith ME
J Pharmacol Exp Ther; 2003 Nov; 307(2):729-36. PubMed ID: 12975490
[TBL] [Abstract][Full Text] [Related]
18. Parkinsonism-inducing neurotoxin MPP+: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA.
Kitayama S; Shimada S; Uhl GR
Ann Neurol; 1992 Jul; 32(1):109-11. PubMed ID: 1642464
[TBL] [Abstract][Full Text] [Related]
19. A model of the sodium dependence of dopamine uptake in rat striatal synaptosomes.
Wheeler DD; Edwards AM; Chapman BM; Ondo JG
Neurochem Res; 1993 Aug; 18(8):927-36. PubMed ID: 8371835
[TBL] [Abstract][Full Text] [Related]
20. Iron deficiency alters dopamine transporter functioning in rat striatum.
Erikson KM; Jones BC; Beard JL
J Nutr; 2000 Nov; 130(11):2831-7. PubMed ID: 11053528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
